Drug Trial Radar · NCT00658970
Evaluation of KX2-391 in Patients With Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Jun 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Planned (sponsor's estimate)
Start
Nov 2007
Primary completion
Mar 2010
Study completion May 2011
Sponsor
- Lead sponsor
- Athenex, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 16, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.
Conditions
- Solid Tumors
- Lymphoma
Interventions
KX2-391Drug
2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine maximum tolerated dose of the drugTime frame: 64 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fox Chase Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.